Search

BACKGROUND: The aim of our study was to examine the impact of the combination of the ratio between metastatic and harvested lymph nodes (RML) and negative lymph node (NLN) count on overall survival (OS) in patients with advanced gastric cancer (GC). METHODS: The clinicopathological data of 2,952 advanced GC patients who received curative resection between 1994 and 2015 were collected. They were divided into four groups according to the RML: 0, 0–0.1, 0.1–0.4, and >0.4. We distinguished survival differences through Kaplan-Meier analysis among the subgroups to investigate the impacts of the RML on OS in advanced GC patients. OS was examined according to clinicopathological variables. Spearman’s correlation coefficient was used to assess the relationships between the RML and metastatic lymph node (MLN) count and NLN count. RESULTS: A total of 1,182 patients were enrolled into the study. The median follow-up time was 39 months (interquartile range 20 to 68 months). The 5-year OS rate of all 1,182 GC patients was 54.4%. Kaplan-Meier survival analysis showed that the median OS declined significantly with increasing RML (5-year survival rate 81.2% vs. 69.1% vs. 42.8% vs. 13.1%, P

BACKGROUND: The influence of pretreatment anemia on the prognosis of patients with advanced gastric cancer (GC) remains controversial. We retrospectively examined the impact of pretreatment anemia on the overall survival (OS) of patients with GC with nonhypoalbuminemia undergoing curative resection. METHODS: The clinicopathological data of 2,916 patients with advanced GC who received a radical gastrectomy from 1994 to 2015 were analyzed. The patients were divided into two subgroups by hemoglobin level

Background: Poly(ADP-ribose) polymerase 1 (PARP1) plays an important role in the process of homologous recombination (HR) repair. The aim of this study was to observe the impact of olaparib (PARP1 inhibitor) on oxaliplatin treatment for XRCC2-defecient colorectal cancer (CRC). Methods: This study examined the influence of treatments on cells with the help of the γ-H2AX foci formation assay. The CCK-8 assay and clonogenic assay were employed to decide the sensitivity of XRCC2-defecient CRC cells to olaparib and/or oxaliplatin. Finally, we investigated the changes in cell cycle and apoptosis with the aid of flow cytometry and western blotting. Results: Gamma-H2AX focusing analysis has reached the conclusion that Olaparab is not the only factor inducing double-strand breaks (DSBs), but it can affect oxaliplatin-induced DSBs of XRCC2-defatted CRC cells. Cell proliferation of XRCC2-defecient CRC cell lines was restrained by combination treatment rather than olaparib or oxaliplatin alone. The flow cytometry and western blotting results gave the description cells exposed to connection treatment had more G2/M-phase cells and induced apoptosis than control. Conclusions: The combination of oxaliplatin and oxaliplatin in the treatment of XRCC2-defecient CRC cells provides a promising method for clinical treatment of XRCC2-defecient CRC.

Metastatic pancreatic tumor is relatively rare in clinic, accounting for only 2–5% of pancreatic cancer. About 50% of metastatic pancreatic tumor are caused by renal cell carcinoma. The symptoms of the tumor have no specificity but strong concealment. Most patients show no difference from ordinary population before the disease worsens. A small number of patients may have abdominal distention and pain, poor appetite, etc. Besides, there may be obstructive jaundice when the tumor blocks the common bile duct, and it can cause pancreatitis in the case of pancreatic duct obstruction. The case to be reported was asymptomatic and a mass of the head of the pancreas was found on examination. The diagnosis of this case depends mainly on ultrasound puncture to obtain pathological results, and CT can exert auxiliary effect during diagnosis. In addition, surgical resection is an effective means to treat this disease, and targeted therapy can be accepted as an alternative therapeutic approach.